Cerus Endovascular and Balt partnered to deliver Contour Neurovascular System in Germany

Cerus Endovascular and Balt this week announced a strategic distribution agreement to provide AB Medica with the exclusive rights to market and sell the Countour Neurovascular System and the Neqstent Coil Assisted Flow Diverter devices.

The distribution agreement is currently limited to Germany. The financial details of the deal were not disclosed.

“Our partnership with Balt, an internationally-recognized pioneer in the neurovascular sector, reflects the strength of our innovative product line and will provide significantly increased awareness and more rapid penetration of both the Contour Neurovascular System and the Neqstent device within Germany, the largest market within the European Union (EU),” president of Cerus Endovascular Stephen Griffin said in a news release. “Physicians in Germany have indicated their desire for greater access to our products and have, therefore, been very supportive of our decision to partner locally with AB Medi…

Read more
  • 0

Balt receives CE Mark for flow diverting shunt

Balt announced that it received CE Mark approval for its Silk Vista flow diverting stent for treating patients with unruptured intracranial aneurysms.

Montmorency, France.-based Balt designed its Silk Vista device for predictable and accurate deployment and high visibility under angiography, adding to its already-CE-Marked Silk Vista baby flow diverter, which has been approved in Europe since 2018.

University of Toronto professor and endovascular neurosurgeon Dr. Vitor Mendes Pereira, who performed the first-in-man case of Silk Vista in Toronto last month, said in a news release that Silk Vista offers improved visibility for treating aneurysms arising off of neurovascular vessels 3.5 mm and larger.

“Balt has provided physicians for decades with unique, life-saving products to treat patients with neurovascular conditions and has been a pioneer in flow diversion technologies,” Balt CEO Pascal Girin said in the release. “The Silk Vista is an exc…

Read more
  • 0

Balt wins IDE approval to start STEM trial

Balt announced that it received FDA investigation device exemption (IDE) for its trial for the treatment of chronic sub-dural hematoma.

The Squid trial for the embolization of the middle meningeal artery (STEM) is a prospective, randomized controlled trial for Balt’s Squid liquid embolic device as a minimally invasive treatment option for the neurological disease.

Irvine, Calif.-based Balt will investigate the safety and effectiveness of middle meningeal artery (MMA) embolization with the Squid device for managing CSDH in both surgical and non-surgical patients.

Co-primary investigator Dr. Adam Arthur of the Semmes-Murphey Neurologic and Spine Institute and University of Tennessee Health Sciences Center said in a news release that the study will help to understand how to treat a major reversible cause of dementia and disability in the elderly.

“The approval of the IDE for the STEM trial represents a significant milestone for Balt as this wil…

Read more
  • 0